Earnings Summary

Jounce Therapeutics, Inc.’s net profit jumped 339299.51% since last year same period to $101.83Mn in the Q4 2022. On a quarterly growth basis, Jounce Therapeutics, Inc. has generated 428.5% jump in its net profits since last 3-months.

Jounce Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.41 - a 35.94% jump from last quarter’s estimates.

Jounce Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.41.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Jounce Therapeutics, Inc.’s return on assets (ROA) stands at -0.14.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Jounce Therapeutics, Inc.’s return on equity (ROE) stands at -0.25.